TY  - JOUR
AU  - Lupattelli, Angela
AU  - Twigg, Michael J.
AU  - Zagorodnikova, Ksenia
AU  - Moretti, Myla E.
AU  - Drozd, Mariola
AU  - Panchaud, Alice
AU  - Rieutord, Andre
AU  - Juraski, Romana Gjergja
AU  - Odalović, Marina
AU  - Kennedy, Debra
AU  - Rudolf, Gorazd
AU  - Juch, Herbert
AU  - Nordeng, Hedvig
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3227
AB  - Purpose: This study aimed at exploring the prevalence of self-reported antenatal and postnatal depressive symptoms by severity across multiple countries and the association between antidepressant treatment in pregnancy and postnatal symptom severity. Materials and methods: This was a multinational web-based study conducted across 12 European countries (n=8069). Uniform data collection was ensured via an electronic questionnaire. Pregnant women at any gestational week and mothers of children with  lt 1 year of age could participate. We used the Edinburgh Postnatal Depression Scale (EPDS) to measure the prevalence of antenatal and postnatal depressive symptoms according to severity, which were corrected by survey weight adjustment (descriptive analysis). Within mothers with a psychiatric disorder (n=173), we estimated the association between antidepressant treatment in pregnancy and postnatal depressive symptom severity, as standardized EPDS mean scores, via the inverse probability of treatment weight (association analysis). Results: In the descriptive analysis (n=8069), the period prevalence of moderate-to-very severe depressive symptoms was higher in the western and eastern regions relative to the northern region, both in the antenatal period (6.8%-7.5% vs 4.3%) and in the postnatal period (7.6% vs 4.7%). One in two mothers with psychiatric disorders used an antidepressant in pregnancy (86 of 173). In the association analysis, women medicated at any time during pregnancy (adjusted beta=-0.34, 95% confidence interval [CI] =-0.66, -0.02) had a significant postnatal symptom severity reduction compared with the nonmedicated counterpart. This effect was larger (beta=-0.74, 95% CI =-1.24, -0.24) when the analysis was restricted to mothers within 6 months after childbirth. Conclusion: The prevalence of self-reported antenatal and postnatal depressive symptoms differs across European countries. Among women with psychiatric disorders, those who had been on treatment with antidepressants during pregnancy were less likely to report postnatal depressive symptoms, particularly within the 6-month period after childbirth, compared with the nonmedicated counterpart.
PB  - Dove Medical Press Ltd, Albany
T2  - Clinical Epidemiology
T1  - Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale
VL  - 10
SP  - 655
EP  - 669
DO  - 10.2147/CLEP.S156210
ER  - 

@article{
author = "Lupattelli, Angela and Twigg, Michael J. and Zagorodnikova, Ksenia and Moretti, Myla E. and Drozd, Mariola and Panchaud, Alice and Rieutord, Andre and Juraski, Romana Gjergja and Odalović, Marina and Kennedy, Debra and Rudolf, Gorazd and Juch, Herbert and Nordeng, Hedvig",
year = "2018",
abstract = "Purpose: This study aimed at exploring the prevalence of self-reported antenatal and postnatal depressive symptoms by severity across multiple countries and the association between antidepressant treatment in pregnancy and postnatal symptom severity. Materials and methods: This was a multinational web-based study conducted across 12 European countries (n=8069). Uniform data collection was ensured via an electronic questionnaire. Pregnant women at any gestational week and mothers of children with  lt 1 year of age could participate. We used the Edinburgh Postnatal Depression Scale (EPDS) to measure the prevalence of antenatal and postnatal depressive symptoms according to severity, which were corrected by survey weight adjustment (descriptive analysis). Within mothers with a psychiatric disorder (n=173), we estimated the association between antidepressant treatment in pregnancy and postnatal depressive symptom severity, as standardized EPDS mean scores, via the inverse probability of treatment weight (association analysis). Results: In the descriptive analysis (n=8069), the period prevalence of moderate-to-very severe depressive symptoms was higher in the western and eastern regions relative to the northern region, both in the antenatal period (6.8%-7.5% vs 4.3%) and in the postnatal period (7.6% vs 4.7%). One in two mothers with psychiatric disorders used an antidepressant in pregnancy (86 of 173). In the association analysis, women medicated at any time during pregnancy (adjusted beta=-0.34, 95% confidence interval [CI] =-0.66, -0.02) had a significant postnatal symptom severity reduction compared with the nonmedicated counterpart. This effect was larger (beta=-0.74, 95% CI =-1.24, -0.24) when the analysis was restricted to mothers within 6 months after childbirth. Conclusion: The prevalence of self-reported antenatal and postnatal depressive symptoms differs across European countries. Among women with psychiatric disorders, those who had been on treatment with antidepressants during pregnancy were less likely to report postnatal depressive symptoms, particularly within the 6-month period after childbirth, compared with the nonmedicated counterpart.",
publisher = "Dove Medical Press Ltd, Albany",
journal = "Clinical Epidemiology",
title = "Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale",
volume = "10",
pages = "655-669",
doi = "10.2147/CLEP.S156210"
}

Lupattelli, A., Twigg, M. J., Zagorodnikova, K., Moretti, M. E., Drozd, M., Panchaud, A., Rieutord, A., Juraski, R. G., Odalović, M., Kennedy, D., Rudolf, G., Juch, H.,& Nordeng, H.. (2018). Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale. in Clinical Epidemiology
Dove Medical Press Ltd, Albany., 10, 655-669.
https://doi.org/10.2147/CLEP.S156210

Lupattelli A, Twigg MJ, Zagorodnikova K, Moretti ME, Drozd M, Panchaud A, Rieutord A, Juraski RG, Odalović M, Kennedy D, Rudolf G, Juch H, Nordeng H. Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale. in Clinical Epidemiology. 2018;10:655-669.
doi:10.2147/CLEP.S156210 .

Lupattelli, Angela, Twigg, Michael J., Zagorodnikova, Ksenia, Moretti, Myla E., Drozd, Mariola, Panchaud, Alice, Rieutord, Andre, Juraski, Romana Gjergja, Odalović, Marina, Kennedy, Debra, Rudolf, Gorazd, Juch, Herbert, Nordeng, Hedvig, "Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale" in Clinical Epidemiology, 10 (2018):655-669,
https://doi.org/10.2147/CLEP.S156210 . .

TY  - JOUR
AU  - Lupattelli, Angela
AU  - Spigset, Olav
AU  - Bjoernsdottir, Ingunn
AU  - Haemeen-Anttila, Katri
AU  - Mardby, Ann-Charlotte
AU  - Panchaud, Alice
AU  - Juraski, Romana Gjergja
AU  - Rudolf, Gorazd
AU  - Odalović, Marina
AU  - Drozd, Mariola
AU  - Twigg, Michael J.
AU  - Juch, Herbert
AU  - Moretti, Myla E.
AU  - Kennedy, Debra
AU  - Rieutord, Andre
AU  - Zagorodnikova, Ksenia
AU  - Passier, Anneke
AU  - Nordeng, Hedvig
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2397
AB  - BackgroundNo previous studies have explored how closely women follow their psychotropic drug regimens during pregnancy. This study aimed to explore patterns of and factors associated with low adherence to psychotropic medication during pregnancy. MethodsMultinational web-based study was performed in 18 countries in Europe, North America, and Australia. Uniform data collection was ensured via an electronic questionnaire. Pregnant women were eligible to participate. Adherence was measured via the 8-item Morisky Medication Adherence Scale (MMAS-8). The Beliefs about Prescribed Medicines Questionnaire (BMQ-specific), the Edinburgh Postnatal Depression Scale (EPDS), and a numeric rating scale were utilized to measure women's beliefs, depressive symptoms, and antidepressant risk perception, respectively. Participants reporting use of psychotropic medication during pregnancy (n = 160) were included in the analysis. ResultsOn the basis of the MMAS-8, 78 of 160 women (48.8%, 95% CI: 41.1-56.4%) demonstrated low adherence during pregnancy. The rates of low adherence were 51.3% for medication for anxiety, 47.2% for depression, and 42.9% for other psychiatric disorders. Smoking during pregnancy, elevated antidepressant risk perception (risk6), and depressive symptoms were associated with a significant 3.9-, 2.3-, and 2.5-fold increased likelihood of low medication adherence, respectively. Women on psychotropic polytherapy were less likely to demonstrate low adherence. The belief that the benefit of pharmacotherapy outweighed the risks positively correlated (r = .282) with higher medication adherence. ConclusionsApproximately one of two pregnant women using psychotropic medication demonstrated low adherence in pregnancy. Life-style factors, risk perception, depressive symptoms, and individual beliefs are important factors related to adherence to psychotropic medication in pregnancy.
PB  - Wiley, Hoboken
T2  - Depression and Anxiety
T1  - Patterns and factors associated with low adherence to psychotropic medications during pregnancy - A cross-sectional, multinational web-based study
VL  - 32
IS  - 6
SP  - 426
EP  - 436
DO  - 10.1002/da.22352
ER  - 

@article{
author = "Lupattelli, Angela and Spigset, Olav and Bjoernsdottir, Ingunn and Haemeen-Anttila, Katri and Mardby, Ann-Charlotte and Panchaud, Alice and Juraski, Romana Gjergja and Rudolf, Gorazd and Odalović, Marina and Drozd, Mariola and Twigg, Michael J. and Juch, Herbert and Moretti, Myla E. and Kennedy, Debra and Rieutord, Andre and Zagorodnikova, Ksenia and Passier, Anneke and Nordeng, Hedvig",
year = "2015",
abstract = "BackgroundNo previous studies have explored how closely women follow their psychotropic drug regimens during pregnancy. This study aimed to explore patterns of and factors associated with low adherence to psychotropic medication during pregnancy. MethodsMultinational web-based study was performed in 18 countries in Europe, North America, and Australia. Uniform data collection was ensured via an electronic questionnaire. Pregnant women were eligible to participate. Adherence was measured via the 8-item Morisky Medication Adherence Scale (MMAS-8). The Beliefs about Prescribed Medicines Questionnaire (BMQ-specific), the Edinburgh Postnatal Depression Scale (EPDS), and a numeric rating scale were utilized to measure women's beliefs, depressive symptoms, and antidepressant risk perception, respectively. Participants reporting use of psychotropic medication during pregnancy (n = 160) were included in the analysis. ResultsOn the basis of the MMAS-8, 78 of 160 women (48.8%, 95% CI: 41.1-56.4%) demonstrated low adherence during pregnancy. The rates of low adherence were 51.3% for medication for anxiety, 47.2% for depression, and 42.9% for other psychiatric disorders. Smoking during pregnancy, elevated antidepressant risk perception (risk6), and depressive symptoms were associated with a significant 3.9-, 2.3-, and 2.5-fold increased likelihood of low medication adherence, respectively. Women on psychotropic polytherapy were less likely to demonstrate low adherence. The belief that the benefit of pharmacotherapy outweighed the risks positively correlated (r = .282) with higher medication adherence. ConclusionsApproximately one of two pregnant women using psychotropic medication demonstrated low adherence in pregnancy. Life-style factors, risk perception, depressive symptoms, and individual beliefs are important factors related to adherence to psychotropic medication in pregnancy.",
publisher = "Wiley, Hoboken",
journal = "Depression and Anxiety",
title = "Patterns and factors associated with low adherence to psychotropic medications during pregnancy - A cross-sectional, multinational web-based study",
volume = "32",
number = "6",
pages = "426-436",
doi = "10.1002/da.22352"
}

Lupattelli, A., Spigset, O., Bjoernsdottir, I., Haemeen-Anttila, K., Mardby, A., Panchaud, A., Juraski, R. G., Rudolf, G., Odalović, M., Drozd, M., Twigg, M. J., Juch, H., Moretti, M. E., Kennedy, D., Rieutord, A., Zagorodnikova, K., Passier, A.,& Nordeng, H.. (2015). Patterns and factors associated with low adherence to psychotropic medications during pregnancy - A cross-sectional, multinational web-based study. in Depression and Anxiety
Wiley, Hoboken., 32(6), 426-436.
https://doi.org/10.1002/da.22352

Lupattelli A, Spigset O, Bjoernsdottir I, Haemeen-Anttila K, Mardby A, Panchaud A, Juraski RG, Rudolf G, Odalović M, Drozd M, Twigg MJ, Juch H, Moretti ME, Kennedy D, Rieutord A, Zagorodnikova K, Passier A, Nordeng H. Patterns and factors associated with low adherence to psychotropic medications during pregnancy - A cross-sectional, multinational web-based study. in Depression and Anxiety. 2015;32(6):426-436.
doi:10.1002/da.22352 .

Lupattelli, Angela, Spigset, Olav, Bjoernsdottir, Ingunn, Haemeen-Anttila, Katri, Mardby, Ann-Charlotte, Panchaud, Alice, Juraski, Romana Gjergja, Rudolf, Gorazd, Odalović, Marina, Drozd, Mariola, Twigg, Michael J., Juch, Herbert, Moretti, Myla E., Kennedy, Debra, Rieutord, Andre, Zagorodnikova, Ksenia, Passier, Anneke, Nordeng, Hedvig, "Patterns and factors associated with low adherence to psychotropic medications during pregnancy - A cross-sectional, multinational web-based study" in Depression and Anxiety, 32, no. 6 (2015):426-436,
https://doi.org/10.1002/da.22352 . .